endocrinotherapy（doctor's choice）

Phase 2Small molecule

endocrinotherapy（doctor's choice） is one of 5 small molecule programs targeting HER2 + Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2 + Breast CancerNot yet recruiting

HER2 + Breast CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in HER2 + Breast Cancer

#DrugCompanyPhaseTrials

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

2 2

Trastuzumab Rezetecan

PPeking Union Medical College Hospital

Phase 3

2 3

Herceptin

OOrganon and Co

Phase 2

2 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 5

endocrinotherapy（doctor's choice）

BBiyun Wang, MD

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Not yet recruiting

HER2 + Breast Cancer

NCT07766772

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib

Unknown status·—·Phase 1/2·NCT05464173·44 enrolled

HER2 + Breast Cancer1 trial

A Single-arm, Exploratory Clinical Study of Sequential Use of Regorafenib in Combination With Pegylated Tyrosine Kinase Inhibitor and Trastuzumab in Combination With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07766772·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for endocrinotherapy（doctor's choice）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — endocrinotherapy（doctor's choice） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for endocrinotherapy（doctor's choice）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biyun Wang, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiyun Wang, MD

endocrinotherapy（doctor's choice）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Breast Cancer1 trial

HER2 + Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News